Skip to main content
. 2015 Jan 20;32(1):32–38. doi: 10.1007/s12288-015-0506-5

Table 3.

Univariate analysis of potential risk factors for development of cGVHD

Group A—with cGVHD (n = 40) n (%) Group B—no cGVHD (n = 37) n (%) P value
Patient related factors
 Median age at transplant 29 31 0.575
 Males 28 (70) 24 (65) 0.631
Diagnosis 0.020
 Acute lymphoid leukemia (ALL) 17 (43) 6 (16)
 Acute myeloid leukemia (AML) 23 (58) 29 (78)
 Biphenotypic leukemia 0 (0) 2 (5)
Baseline risk 0.138
 Good (or standard) risk 2 4
 Intermediate risk 7 14
 Poor risk 25 14
 Not known 6 5
 Relapse/refractory disease at transplant 5 (12) 10 (27) 0.231
Donor related factors
 Median donor age, years 32 33 0.860
 ABO mismatch transplants 20 (50) 12 (32) 0.118
 Gender mismatched transplants 25 (63) 15 (41) 0.054
 Female to male transplants 17 (43) 6 (16) 0.012
 Stem cell source 0.855
 Bone marrow 2 (5) 3 (8)
Umbilical cord 1 (3) 1 (3)
 Peripheral blood stem cells 37 (93) 33 (89)
 Degree of HLA matching 0.121
 BM or PBSC
  Full matched (6/6 or 10/10) 34 (85) 27 (73)
  1 antigen mismatch 5 (13) 4 (11)
  Haplo-identical transplant 0 (0) 5 (14)
  Cord transplants 1 (3) 1 (3)
Transplant related factors
 Type of transplant 0.321
 Matched related transplant 35 (88) 30 (81)
 Matched unrelated transplant 5 (13) 5 (14)
 Haplo-identical transplant 0 (0) 2 (5)
 Type of conditioning regimen 0.093
 Full intensity 18 (45) 9 (24)
 Reduced intensity 22 (55) 28 (76)
 Total body irradiation used 20 (50) 12 (32) 0.118
 ATG used 5 (13) 7 (19) 0.438
 Graft versus host disease prophylaxis 0.224
 CsA+MTX 30 (75) 23 (62)
 CsA+MMF 10 (25) 14 (38)
 Cell doses infused
  TNC (×108)/kg 7.10 6.63 0.913
  CD34 (×106)/kg 5.11 5.12 0.899
  CD3 (×106)/kg 147.80 177.65 0.039
 Prior acute GVHD, any grade, n (%) 21 (53) 13 (35) 0.630
 Day100 median absolute lymphocyte count (×109/L) 1.23 (n = 39) 1.41 (n = 28) 0.589
 Day180 median absolute lymphocyte count (×109/L) 1.61 (n = 39) 2.05 (n = 22) 0.131